GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

GoodRx (NASDAQ:GDRX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

GDRX has been the subject of a number of other reports. Barclays assumed coverage on GoodRx in a report on Monday, December 8th. They issued an “underweight” rating and a $3.00 price target for the company. Citigroup lowered their target price on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Mizuho decreased their price target on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GoodRx currently has an average rating of “Hold” and an average price target of $4.91.

View Our Latest Stock Analysis on GoodRx

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $2.68 on Friday. The firm has a market cap of $909.67 million, a PE ratio of 29.78, a price-to-earnings-growth ratio of 1.02 and a beta of 1.45. The company has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $3.73. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. GoodRx has a 12-month low of $2.61 and a 12-month high of $5.81.

GoodRx (NASDAQ:GDRX – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. During the same period in the prior year, the business earned $0.08 earnings per share. GoodRx’s revenue was up .4% on a year-over-year basis. On average, equities research analysts anticipate that GoodRx will post 0.13 EPS for the current fiscal year.

Institutional Trading of GoodRx

A number of large investors have recently modified their holdings of GDRX. Quarry LP acquired a new position in GoodRx during the 3rd quarter valued at about $33,000. Boothbay Fund Management LLC bought a new stake in shares of GoodRx during the third quarter valued at approximately $43,000. Shay Capital LLC acquired a new position in shares of GoodRx during the third quarter worth approximately $47,000. Cetera Investment Advisers acquired a new position in shares of GoodRx during the second quarter worth approximately $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in GoodRx in the 2nd quarter worth approximately $55,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Further Reading